期刊文献+

中药药物警戒思想的挖掘与实践 被引量:24

Pharmacovigilance of Chinese Medicine: Mining and Practice
下载PDF
导出
摘要 中药传统安全用药思想源远流长,内容丰富。随着中药安全性事件的曝光,人们对传统安全用药思想与警戒实践的发掘愈发重视与完善,赋予了中药药物警戒思想新的内涵,填补了中药安全性研究的空白。中药药物警戒思想贯穿于中药从采收到临床应用整个生命周期,是临床安全有效应用中药的重要保障。虽然中药药物警戒工作刚刚起步,但不可否认的是,坚持践行中药药物警戒思想势必能为临床带来更大的获益,推动中药现代化进程。 The safe medication theory of Traditional Chinese Medicine( TCM) is rich and has a long history.With the exposure of TCM safe incidents,people increasingly give attention to mining of safe medication theory and pharmacovigilance practice. The mining works are giving new meaning to Pharmacovigilance of Chinese Medicine,and filling the gap in TCM safety research. Pharmacovigilance of Chinese Medicine runs through the medicines' whole life that from gather medicinal herbs to clinical application,which is an important guarantee for clinical safety and effective application. Although the work of Pharmacovigilance of Chinese Medicine has just started,it is undeniable that insisting on practice Pharmacovigilance of Chinese Medicine is bound to bring more clinical benefit,and promote the process of TCM modernization.
出处 《药物流行病学杂志》 CAS 2016年第7期405-408,共4页 Chinese Journal of Pharmacoepidemiology
基金 国家食品药品监督管理总局药品评价中心项目 中华中医药学会研究与评价专项课题(编号:CACMRE2014-A003)
关键词 中药 药物警戒 安全用药 Traditional Chinese medicine Pharmacovigilance Safe
  • 相关文献

参考文献2

二级参考文献26

  • 1Tsintis P, La Mache E. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications[J]. Drug Saf,2004,27(8) :509-517.
  • 2Cobert BL. Manual of Drug Safety and Pharmacovigitance [ M ]. 2nd ed. Jones and Bartlett Publishers, 2007.
  • 3Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance [ J ]. Pharmacoepidemiol Drug Saf, 2003, 12(1) :17-29.
  • 4FDA. Challenges and Opportunities Report [ EB/OL]. http ://www. fda. gov/ScienceResearch/SpecialTopics/ Critical-Pathlnitiative/ CriticalPathOpportunitiesReports/ ucm077 262. htm , 2004/2010-06-02.
  • 5Di Masi JA, Hansen RW, Grabowski HG, et al. The price of innovation : new estimates of drug development costs [ J ]. J Health Econ ,2003,22 : 151-185.
  • 6Mann RD, Andrews EB. Pharmacovigilance [ M ]. 2nd ed. New Jersey: John Wiley & Sons, Ltd. , 2007.
  • 7Leiderman DB. Risk management of drug products and the U.S. Food and Drug Administration: evolution and context [ J ]. Drug Alcohol Depend,2009,105 ( Suppl 1 ) : S9-S13.
  • 8EMA. Guideline on Risk Management Systems for Medical Products for Human Use [ EB/OL ]. http ://www. ema. europa. eu/pdfs/human/euleg/9626805en, pdf, 2005/2010-06- 02.
  • 9ICH E2E. Pharmacovigilance Planning [ EB/OL ]. http :// www. ich. org/cache/compo/475 - 272 - 1. html # E2E, 2004/2010-06-02.
  • 10FDA Guidance for Industry: Premarketing Risk Assessment [ EB/OL]. http ://www. fda. gov/downloads/Regulatorylnformation/ Guidanees/ uem12695 8. pdf , 2005/2010-06-02.

共引文献13

同被引文献320

引证文献24

二级引证文献152

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部